PULMONARY ARTERIAL HYPERTENSION (PAH)
Clinical trials for PULMONARY ARTERIAL HYPERTENSION (PAH) explained in plain language.
Never miss a new study
Get alerted when new PULMONARY ARTERIAL HYPERTENSION (PAH) trials appear
Sign up with your email to follow new studies for PULMONARY ARTERIAL HYPERTENSION (PAH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection tested to boost heart power in serious lung pressure disease
Disease control Not yet recruitingThis study is testing whether adding an injectable medication called treprostinil to a patient's current oral therapy can improve heart function in people with intermediate-risk pulmonary arterial hypertension (PAH). All 32 participants will receive the injection alongside their …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE2 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Apr 04, 2026 00:35 UTC
-
Three-drug attack on deadly lung pressure disease
Disease control Not yet recruitingThis study is testing whether starting treatment with three different medications right away is better for people newly diagnosed with pulmonary arterial hypertension (PAH), a serious condition that causes high blood pressure in the lungs. It will involve 25 participants who will…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE2 • Sponsor: Philipps University Marburg • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New hope for PAH patients: study tests Drug's power to heal lung and heart damage
Disease control Not yet recruitingThis study is testing if a new drug called sotatercept can help control the progression of pulmonary arterial hypertension (PAH), a serious lung and heart condition. Researchers will use advanced imaging scans to see if the drug reduces harmful tissue changes in the lungs' blood …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Brest • Aim: Disease control
Last updated Apr 03, 2026 14:42 UTC
-
New hope for damaged lung arteries: study tests Drug's repair potential
Disease control Not yet recruitingThis study aims to understand if the medication sotatercept can help repair and improve the structure of damaged lung arteries in people with pulmonary arterial hypertension. Researchers will use specialized imaging techniques to look inside the lung blood vessels of 30 participa…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: Franz Rischard, DO • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Can a Heart-Lung pill fight a Parasite's Long-Term damage?
Disease control Not yet recruitingThis study aims to understand the long-term effects of a medication called selexipag for people with a specific type of high blood pressure in the lungs caused by a parasitic infection (schistosomiasis). Researchers will compare the health outcomes of about 30 patients who receiv…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: Caio Júlio César dos Santos Fernandes • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New hope for PAH patients: testing a novel drug to ease heart strain
Disease control Not yet recruitingThis study is testing an experimental drug called REGN13335 for adults with Pulmonary Arterial Hypertension (PAH), a serious lung and heart condition. The goal is to see if adding this new drug to a patient's current standard medications can better control the disease by reducing…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
Groundbreaking stem cell trial aims to save tiniest Babies' lungs
Disease control Not yet recruitingThis early-stage study is testing a new stem cell treatment called PNEUMOSTEM® in very premature babies who develop high blood pressure in their lungs soon after birth. Researchers will give a single dose of the cells directly into the windpipe to see if it is safe and if it can …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE1 • Sponsor: Samsung Medical Center • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC
-
Dual-Drug attack on deadly lung pressure in High-Risk heart patients
Disease control Not yet recruitingThis study compares starting treatment with two oral medications versus one medication for people newly diagnosed with pulmonary arterial hypertension (PAH) who also have at least two other heart-related conditions like high blood pressure or diabetes. It aims to find the safest …
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Could a simpler pill replace multiple daily inhalations for lung disease patients?
Symptom relief Not yet recruitingThis study looks at whether switching adults with pulmonary arterial hypertension (PAH) from an inhaled medication that requires multiple daily uses to a twice-daily oral pill improves their quality of life and makes it easier to stick with treatment. Researchers will follow 32 p…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: University of Sao Paulo General Hospital • Aim: Symptom relief
Last updated Apr 03, 2026 14:42 UTC
-
Survey reveals where patients and families search for answers about serious lung condition
Knowledge-focused Not yet recruitingThis study aims to learn where patients with pulmonary hypertension and their caregivers look for health information and what topics they search for most. Researchers will survey 100 patients and 100 caregivers using a short questionnaire about their information sources, satisfac…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: University of Sao Paulo General Hospital • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:41 UTC
-
Gene hunt launched for rare, deadly vascular duo
Knowledge-focused Not yet recruitingThis study aims to find the genetic clues that explain why some people with a rare liver blood vessel defect develop a dangerous lung pressure condition. Researchers will analyze DNA from patients with both conditions and their close family members. The long-term goal is to use t…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: Prof. Valérie Mc Lin • Aim: Knowledge-focused
Last updated Mar 30, 2026 14:32 UTC
-
Searching for environmental clues to a rare, incurable lung disease
Knowledge-focused Not yet recruitingThis study aims to understand if environmental and occupational exposures play a role in causing pulmonary arterial hypertension (PAH), a rare and currently incurable disease. Researchers will compare 150 newly diagnosed patients with PAH to patients with a different form of lung…
Matched conditions: PULMONARY ARTERIAL HYPERTENSION (PAH)
Sponsor: Poitiers University Hospital • Aim: Knowledge-focused
Last updated Mar 27, 2026 12:39 UTC